Biosimilar drugs saved $7.9 billion dollars in 2020 alone, more than tripling the $2.5 billion saved in 2019, according to the latest report from the Association for Accessible Medicines.
The goal of the pilot program is to allow American and European assessors the ability to concurrently exchange their views with applicants on scientific issues during the development phase of complex generic/hybrid products.